Thr322
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr322  -  SMAD1 (human)

Site Information
sNVNRNStIENTRRH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25802105

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
brain cancer ( 1 ) , glioblastoma ( 1 ) , glioma ( 1 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , pancreatic cancer ( 1 ) , pancreatic carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
HGK (human) ( 1 ) , MINK (human) ( 1 ) , TNIK (human) ( 1 )
Kinases, in vitro:
HGK (human) ( 1 ) , MINK (human) ( 1 ) , TNIK (human) ( 1 )
Treatments:
okadaic_acid ( 1 )

Downstream Regulation
Effects of modification on SMAD1:
activity, inhibited ( 1 ) , phosphorylation ( 1 )

References 

1

Kaneko S, et al. (2011) Smad inhibition by the Ste20 kinase Misshapen. Proc Natl Acad Sci U S A 108, 11127-32
21690388   Curated Info